The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Sharon Elad; Noam Yarom; Yehuda Zadik; Michal Kuten-Shorrer; Stephen T. Sonis

doi:10.3322/caac.21704

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Sharon Elad^*, Noam Yarom, Yehuda Zadik, Michal Kuten-Shorrer, Stephen T. Sonis

^*Corresponding author for this work

ZAMERET

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Abstract

Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.

Original language	American English
Pages (from-to)	57-77
Number of pages	21
Journal	Ca-A Cancer Journal for Clinicians
Volume	72
Issue number	1
DOIs	https://doi.org/10.3322/caac.21704
State	Published - 1 Jan 2022

Bibliographical note

Funding Information:
No specific funding was disclosed. Sharon Elad reports a grant from the National Institutes of Health through the National Dental Practice‐Based Research Network; Consultation fees from Falk Pharma GmbH, all are outside the submitted work. Stephen T. Sonis is an employee of Biomodels, LLC, and Primary Endpoint Solutions, LLC; he owns equity in both companies and reports participation in scientific advisory boards as a component of his employment; both companies assist industry, government, and academics to study and enable drugs, biologicals, and devices to treat patients for a variety of indications, including oral mucositis, and their employees are prohibited from having equity in any of the companies with which they work. Noam Yarom, Yehuda Zadik, and Michal Kuten‐Shorrer had no disclosures. Disclosures:

Funding Information:
We thank Mr. Glen Hinz, BFA, from the Medical Illustration School of Art, College of Art and Design, Rochester Institute of Technology, for creation of the pathobiology illustration.

Publisher Copyright:
© 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society

Keywords

Antineoplastic Agents/adverse effects
Hematopoietic Stem Cell Transplantation/adverse effects
Humans
Mouth Mucosa/drug effects
Neoplasms/therapy
Oral Ulcer/diagnosis
Prevalence
Quality of Life
Radiation Injuries/diagnosis
Severity of Illness Index
Stomatitis/diagnosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3322/caac.21704

Cite this

@article{0b45e99eb7ae462fb6f9a3da75a938b1,

title = "The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies",

abstract = "Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.",

keywords = "Antineoplastic Agents/adverse effects, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Mouth Mucosa/drug effects, Neoplasms/therapy, Oral Ulcer/diagnosis, Prevalence, Quality of Life, Radiation Injuries/diagnosis, Severity of Illness Index, Stomatitis/diagnosis",

author = "Sharon Elad and Noam Yarom and Yehuda Zadik and Michal Kuten-Shorrer and Sonis, {Stephen T.}",

note = "Funding Information: No specific funding was disclosed. Sharon Elad reports a grant from the National Institutes of Health through the National Dental Practice‐Based Research Network; Consultation fees from Falk Pharma GmbH, all are outside the submitted work. Stephen T. Sonis is an employee of Biomodels, LLC, and Primary Endpoint Solutions, LLC; he owns equity in both companies and reports participation in scientific advisory boards as a component of his employment; both companies assist industry, government, and academics to study and enable drugs, biologicals, and devices to treat patients for a variety of indications, including oral mucositis, and their employees are prohibited from having equity in any of the companies with which they work. Noam Yarom, Yehuda Zadik, and Michal Kuten‐Shorrer had no disclosures. Disclosures: Funding Information: We thank Mr. Glen Hinz, BFA, from the Medical Illustration School of Art, College of Art and Design, Rochester Institute of Technology, for creation of the pathobiology illustration. Publisher Copyright: {\textcopyright} 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society",

year = "2022",

month = jan,

day = "1",

doi = "10.3322/caac.21704",

language = "American English",

volume = "72",

pages = "57--77",

journal = "Ca-A Cancer Journal for Clinicians",

issn = "0007-9235",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

AU - Elad, Sharon

AU - Yarom, Noam

AU - Zadik, Yehuda

AU - Kuten-Shorrer, Michal

AU - Sonis, Stephen T.

N1 - Funding Information: No specific funding was disclosed. Sharon Elad reports a grant from the National Institutes of Health through the National Dental Practice‐Based Research Network; Consultation fees from Falk Pharma GmbH, all are outside the submitted work. Stephen T. Sonis is an employee of Biomodels, LLC, and Primary Endpoint Solutions, LLC; he owns equity in both companies and reports participation in scientific advisory boards as a component of his employment; both companies assist industry, government, and academics to study and enable drugs, biologicals, and devices to treat patients for a variety of indications, including oral mucositis, and their employees are prohibited from having equity in any of the companies with which they work. Noam Yarom, Yehuda Zadik, and Michal Kuten‐Shorrer had no disclosures. Disclosures: Funding Information: We thank Mr. Glen Hinz, BFA, from the Medical Illustration School of Art, College of Art and Design, Rochester Institute of Technology, for creation of the pathobiology illustration. Publisher Copyright: © 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.

AB - Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.

KW - Antineoplastic Agents/adverse effects

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Mouth Mucosa/drug effects

KW - Neoplasms/therapy

KW - Oral Ulcer/diagnosis

KW - Prevalence

KW - Quality of Life

KW - Radiation Injuries/diagnosis

KW - Severity of Illness Index

KW - Stomatitis/diagnosis

UR - http://www.scopus.com/inward/record.url?scp=85118205785&partnerID=8YFLogxK

U2 - 10.3322/caac.21704

DO - 10.3322/caac.21704

M3 - Review article

C2 - 34714553

AN - SCOPUS:85118205785

SN - 0007-9235

VL - 72

SP - 57

EP - 77

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

IS - 1

ER -

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this